These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 35045221)

  • 21. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    González-Martín A; Chung HC; Saada-Bouzid E; Yanez E; Senellart H; Cassier PA; Basu B; Corr BR; Girda E; Dutcus C; Okpara CE; Ghori R; Jin F; Groisberg R; Lwin Z
    Gynecol Oncol; 2024 Jul; 186():182-190. PubMed ID: 38718741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
    N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
    Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
    Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
    Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
    Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab for Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
    N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
    Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
    Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
    Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
    Yang JC; Han B; De La Mora Jiménez E; Lee JS; Koralewski P; Karadurmus N; Sugawara S; Livi L; Basappa NS; Quantin X; Dudnik J; Ortiz DM; Mekhail T; Okpara CE; Dutcus C; Zimmer Z; Samkari A; Bhagwati N; Csőszi T
    J Thorac Oncol; 2024 Jun; 19(6):941-953. PubMed ID: 38159809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
    Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
    Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
    Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK;
    J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898
    [No Abstract]   [Full Text] [Related]  

  • 39. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
    N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.